Short chain fatty acids (SCFAs) (Gut 1995; 37: 684-689) 
of the study was to assess the kinetic parameters, Vmax and Km, of the complete oxidation of short chain fatty acids and glucose by human colonocytes and to explore whether a metabolic abnormality could be As in controls, the Km value of glucose (713 (50) p2mol/l) was not significantly different from the Km value of acetate (Table) . Figure 2 shows the production rates of ATP as a function of substrate concentrations. The values of ATP production are calculated on the basis that complete oxidation of 1 mol acetate, propionate, butyrate, and glucose provides 10, 18, 27, and 36 mol of ATP, respectively.18 At each concentration the production rates of ATP were similar comparing acetate, propionate, and glucose but significantly higher for butyrate in both UC and controls.
Discussion
The concept of SCFAs being a critical luminal nutrient source for the colonic mucosal cells and of there being a potential 'metabolic block' in UC was originally proposed by Roediger in 1980.7 14 In cell suspensions of isolated human colonocytes (resection specimens obtained from patients with carcinoma of the colon), butyrate accounted for more than 70% of the oxygen consumption, and the hypothesis was put forward that fatty acids of anaerobic bacteria are an important source of energy for the colonic mucosa.7 In patients with quiescent and acute UC the oxidation rates of butyrate to CO2 and ketones were significantly lower than in control tissues, and the decrease correlated with the state of the disease.14 Enhanced glucose and glutamine utilisation compensated for the decreased oxidation of butyrate, as measured by lactate and ammonia production, respectively. It was therefore suggested that failure of fatty acid (butyrate) oxidation in UC is an expression of an energy deficiency disease of the colonic mucosa. 22 or even increased in this setting. 23 The last study by Roediger et a123 measured luminal concentrations of SCFAs in patients with UC, which were graded according to mucosal changes into mild, moderate, or severe inflammatory activity. Concentrations of acetate, propionate, and butyrate were all increased in severe UC whereas only butyrate concentrations were significantly raised in patients with mild and moderate inflammatory activity. The authors suggested that the persistently raised concentrations of butyrate in all severities of mucosal inflammation could reflect the previously shown inability of butyrate utilisation in UC. 14 In that case, it would be less plausible that the response of UC to SCFA administration is mediated through increased accessibility of butyrate.
To our knowledge this is the first study to investigate the colonic mucosal metabolism in patients with UC by use of isolated colonocytes since the study performed by Roediger in 1980.14 The similar oxidation of butyrate in controls and patients with UC shown by our study is in contrast with the results previously obtained.14 With reference to luminal concentrations, Roediger considered butyrate concentrations of 10 mmol/l as physiological. 14 By use of separated cells, however, not only the mucosal cell membranes become exposed to the surrounding solution but also the serosal parts, which in vivo are exposed to SCFA concentrations of about 1/100 to 1/1000 of the luminal concentrations,22425 and recent studies on isolated rat colonocytes '5 have shown Km values of SCFA oxidation in the range of 0.2-0.5 mmolI1 indicating that intracellular concentrations may be closer to portal rather than luminal concentrations. The incubations in our study were therefore performed in the presence of extracellular concentrations ranging from 0.125 to 2 mmol/l. The resultant curves obeyed MichaelisMenten kinetics for all substrates permitting the determination of the kinetic parameters, Vmax (maximum rate of metabolism) and Km (the substrate concentration at which the reaction rate has half its maximum value) showing that the maximum rate of SCFA oxidation by isolated colonocytes is well achieved at concentrations around 2 mmol/l (Table) 31 This study showed that isolated human colonocytes can utilise each of the major SCFAs. No major differences in the apparent Vmax values of CO2 production from acetate, propionate, and butyrate were seen (Table) . In the assessment of the relative importance of the individual SCFAs in the energy generating process, however, the order of energy contribution may be of more relevance. Calculated on the basis that complete oxidation of 1 mol acetate, propionate, and butyrate provides 10, 18 , and 27 mol ATP, respectively,18 a relative order of energy contribution of butyrate>acetate=propionate is found (Fig 2) .
The importance of butyrate as an energy source for the colonic mucosa is further emphasised by the finding that it had the lowest Km showing that butyrate may serve as a more readily oxidised fuel than propionate and acetate at low concentrations (<200 Rmol/1).
In vivo, the colonic mucosa is exposed to very high luminal concentrations of SCFAs, but intracellular concentrations are unknown and may be closer to portal blood concentrations, which are in the range of 114-258 ,moI/l for acetate, 32-88 ,umol/l for propionate, and 9-29 ,mol/l for butyrate2 24 25 - The present lack of a corresponding increase in the rate of CO2 production is in agreement with the results of Chapman.3' The apparent Vmax of glucose oxidation was significantly lower compared with the Vmax values of SCFA oxidation. However, assuming that complete oxidation of 1 mol glucose provides 36 mol of ATP,18 the maximum energy contribution from glucose oxidation is in fact comparable with the energy contribution from acetate and propionate (Fig 2) showing that the energy requirements of human colonocytes may be supported by oxidation of blood borne glucose.
This study has shown the ability of isolated human colonic cells to utilise each of the three major SCFAs. The considerably lower Km of butyrate oxidation shows that butyrate is metabolised more avidly than acetate and propionate at low concentrations and supports a specific role of butyrate as an energy source for the colonic mucosa. Although other effects of SCFAs than their role as energetic fuels may provide additional explanations as to how they seem to improve UC, the results suggest that SCFA solutions should include butyrate in the treatment of UC, not because increased luminal concentrations may overcome a metabolic block but because butyrate seems to be an excellent fuel for colonocytes in patients with UC. 
